期刊
ONCOGENE
卷 41, 期 11, 页码 1600-1609出版社
SPRINGERNATURE
DOI: 10.1038/s41388-022-02196-y
关键词
-
资金
- National Science Centre (Poland) [2015/18/E/NZ5/00723, 2018/31/N/NZ5/01438, 2019/32/T/NZ5/00241]
- Ministry of Education and Science (Poland) [013/RID/2018/19]
- Medical Research Council (MRC, UK) Molecular Haematology Unit (MHU) grant [MC_UU_00016/6]
- Engineering and Physical Sciences Research Council (EPSRC) [2119788, EP/R513295/1]
- MRC [MC_UU_00016/6] Funding Source: UKRI
This study reveals the potential mechanisms underlying limited activity of venetoclax in MLLr BCP-ALL and identifies auranofin as a sensitizer for venetoclax, independently of the p53 pathway. Auranofin enhances the sensitivity of MLLr BCP-ALL to venetoclax by upregulating the NOXA pro-apoptotic protein and inducing apoptotic cell death. These findings suggest a potential effective drug combination for the treatment of MLLr BCP-ALL patients.
The prognosis for B-cell precursor acute lymphoblastic leukemia patients with Mixed-Lineage Leukemia (MLL) gene rearrangements (MLLr BCP-ALL) is still extremely poor. Inhibition of anti-apoptotic protein BCL-2 with venetoclax emerged as a promising strategy for this subtype of BCP-ALL, however, lack of sufficient responses in preclinical models and the possibility of developing resistance exclude using venetoclax as monotherapy. Herein, we aimed to uncover potential mechanisms responsible for limited venetoclax activity in MLLr BCP-ALL and to identify drugs that could be used in combination therapy. Using RNA-seq, we observed that long-term exposure to venetoclax in vivo in a patient-derived xenograft model leads to downregulation of several tumor protein 53 (TP53)-related genes. Interestingly, auranofin, a thioredoxin reductase inhibitor, sensitized MLLr BCP-ALL to venetoclax in various in vitro and in vivo models, independently of the p53 pathway functionality. Synergistic activity of these drugs resulted from auranofin-mediated upregulation of NOXA pro-apoptotic protein and potent induction of apoptotic cell death. More specifically, we observed that auranofin orchestrates upregulation of the NOXA-encoding gene Phorbol-12-Myristate-13-Acetate-Induced Protein 1 (PMAIP1) associated with chromatin remodeling and increased transcriptional accessibility. Altogether, these results present an efficacious drug combination that could be considered for the treatment of MLLr BCP-ALL patients, including those with TP53 mutations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据